Enhancing Small Molecule Solubility: Advancing Liposomal Drug Delivery with FR-JET® Copy
We’re excited to share a case study on our successful collaboration with Glatt, highlighting how our FR-JET® technology enables superior liposomal formulation.
Key insights from our feasibility study:
- Successfully formulated naproxen-loaded liposomes using various lipid compositions, highlighting new drug delivery possibilities.
- Achieved liposome sizes ≤150 nm and a PDI of ≤0.14, demonstrating robust and efficient formulation screening.
- Showcased FR-JET® technology’s potential to streamline liposomal research, and optimize scale-up manufacturing for future applications.
About LEON
leon-nanodrugs GmbH is a Munich-based pharmatech company specializing in the development of devices for the encapsulation of genetic material and other pharmaceutical active substances into nanocarriers, such as lipid nanoparticles (LNPs). LEON builds its innovative solutions based on its proprietary FR-JET® Technology. Its portfolio of devices, NANOscreen® for simplified formulation screening, NANOlab® for process development, and NANOme® and NANOus® for GMP aseptic manufacturing, enable faster route to clinical batches and are suitable for both individualised scales and commercial production.
LEON’s platform is aimed at enabling pharma companies, small biotech, research institutes, as well as CDMOs, to take full advantage of the significant progress being made in advanced therapies.
For general information and enquiries please email info@leon-nanodrugs.com